Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Anebulo Pharmaceuticals, Inc. (ANEB : NSDQ)
 
 • Company Description   
Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.68 Daily Weekly Monthly
20 Day Moving Average: 16,765 shares
Shares Outstanding: 41.08 (millions)
Market Capitalization: $69.02 (millions)
Beta: -0.98
52 Week High: $3.08
52 Week Low: $0.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 49.07% 41.00%
12 Week 75.00% 46.82%
Year To Date 0.00% -6.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1017 Ranch Road 620 South SUITE 107
-
LAKEWAY,TX 78734
USA
ph: 512-598-0931
fax: -
ir@anebulo.com http://www.anebulo.com
 
 • General Corporate Information   
Officers
Richard Anthony Cunningham - Chief Executive Officer
Joseph F. Lawler - Chairman of the Board of Directors
Daniel George - Chief Financial Officer
Aron R. English - Director
Jason Aryeh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 034569103
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 09/24/25
Share - Related Items
Shares Outstanding: 41.08
Most Recent Split Date: (:1)
Beta: -0.98
Market Capitalization: $69.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/24/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.13
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: 55.56%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -90.11
12/31/24 - -119.54
ROA
06/30/25 - -
03/31/25 - -84.53
12/31/24 - -108.08
Current Ratio
06/30/25 - -
03/31/25 - 25.29
12/31/24 - 17.51
Quick Ratio
06/30/25 - -
03/31/25 - 25.29
12/31/24 - 17.51
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.33
12/31/24 - 0.36
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©